Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: Follow up of a pilot study and promising future directions

Australasian Journal of Dermatology

Volumn 55, Issue 1, 2014, Pages 63-69

  Tu, Jenny ^a   Foster, Rachael S ^a   Bint, Lewis J ^a   Halbert, Anne R ^a  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

Author keywords

angiofibroma; sirolimus; topical rapamycin; tuberous sclerosis

Indexed keywords

RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; FEMALE; HEMANGIOFIBROMA; HEMANGIOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PATIENT SATISFACTION; PHARMACIST; PILOT STUDY; POWDER; PRESCHOOL CHILD; SCHOOL CHILD; SKIN MANIFESTATION; TABLET FORMULATION; TERTIARY CARE CENTER; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; YOUNG ADULT; ANGIOFIBROMA; COMPLICATION; FOLLOW UP; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ANGIOFIBROMA; ANTIBIOTICS, ANTINEOPLASTIC; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PILOT PROJECTS; SIROLIMUS; TUBEROUS SCLEROSIS; YOUNG ADULT;

EID: 84892834133     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12125     Document Type: Article

References (14)

1. Curatolo P, Bombardieri R, Jozwiak S,. Tuberous sclerosis. Lancet 2008; 372: 657-668.
2. Foster R, Bint L, Halbert A,. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas. J. Dermatol. 2012; 53: 52-56.
3. Haemel AK, O'Brian AL, Teng JM,. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch. Dermatol. 2010; 146: 715-718.
4. DeKlotz CM, Ogram AE, Singh S, et al. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch. Dermatol. 2011; 147: 1116-1117.
5. Mutizwa M, Berk D, Anadkat M,. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1 mg mL)) in two patients with tuberous sclerosis. Br. J. Dermatol. 2011; 165: 922-923.
6. Wataya-Kaneda M, Tanaka M, Nakamura A, et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br. J. Dermatol. 2011; 165: 912-916.
7. Truchuelo T, Díaz-Ley B, Ríos L, et al. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Dermatol. Online J. 2012; 18: 15.
8. Kaufman McNamara E, Curtis AR, Fleischer AB Jr,. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J. Dermatolog. Treat. 2012; 23: 46-48.
9. Koenig M, Hebert A, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012; 12: 121-126.
10. Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis-associated facial angiofibroma. J. Eur. Acad. Dermatol. Venereol. 2012; 26: 1315-1318.
11. Wheless JW, Almoazen H,. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. J. Child Neurol. 2013; 28: 933-936.
12. Tanaka M, Wataya-Kaneda M, Nakamura A, et al. First left-right comparative study of topical rapamycin versus vehicle for facial angiofibromas in patients with tuberous sclerosis complex. Br. J. Dermatol. 2013; doi: 10.1111/bjd.12567. [Epub ahead of print].
13. Madke B,. Topical rapamycin (sirolimus) for facial angiofibromas. Indian Dermatol. Online J. 2013; 4: 54-57.
14. Wataya-Kaneda M, Tanaka M, Nakamura A, et al. A novel application of topical rapamycin formulation, an inhibitor of mTOR, for patients with hypomelanotic macules in tuberous sclerosis complex. Arch. Dermatol. 2012; 148: 138-139.